Key Highlights
- October 26, 2026 is the FDA target action date for bepirovirsen, an antisense medicine for adults with chronic hepatitis B, filed by GSK (NYSE:GSK) under priority review. The date is 10 days away, so the decision is upcoming. Ionis (NASDAQ:IONS) licensed the drug in 2019.
- 10 to 12 percent is the tiered royalty range Ionis (NASDAQ:IONS) is eligible to earn on net sales of bepirovirsen, according to the company release. Ionis has also received an upfront payment, a license fee and milestones, and can earn further regulatory and sales milestones.
- 29 countries took part in the two Phase 3 trials, B-Well 1 and B-Well 2, where the company says functional cure rates were significantly higher with bepirovirsen plus standard care than with standard care alone. Standard care alone produces functional cure in about 1 percent of patients.
- 3 other regulators are reviewing the drug: the European Medicines Agency, China and Japan, which is a global filing for Ionis (NASDAQ:IONS). The FDA date on October 26 is the first test and the only one with a fixed day.
What the FDA Is Reviewing
Bepirovirsen is an antisense oligonucleotide, a short strand of genetic material that binds viral RNA to cut production of hepatitis B proteins. GSK's new drug application for adults with chronic hepatitis B was accepted for priority review, which targets action within six months instead of ten, with breakthrough therapy designation added after fast track status in February 2024. The FDA target action date is October 26, 2026. The B-Well trials enrolled patients already on nucleos(t)ide analogue treatment, and the primary goal was functional cure, meaning sustained loss of the surface antigen.
What Ionis Actually Earns
Ionis discovered bepirovirsen and licensed it to GSK in 2019, so GSK runs development and sales. Ionis keeps tiered royalties of 10 to 12 percent on net sales plus possible milestones, which is a smaller share than owning the product. Ionis (NASDAQ:IONS) cannot control launch timing or pricing. The release did not give functional cure percentages from the trials, so the size of the benefit over the roughly 1 percent standard care rate is not quantified here.
Risks and Timing
Priority review does not guarantee approval, and a delay or complete response letter would affect sentiment. October 26 is a Monday, and the FDA can act before a goal date. The company described safety as acceptable and consistent with prior studies, but longer follow-up and real-world use matter for a chronic infection. GSK sets uptake. The trial data were scheduled for the EASL meeting in May 2026.
Where Things Stand
It depends. Ionis (NASDAQ:IONS) should benefit from an approval through royalties and milestones, but the economics are a share of GSK sales, not full ownership, and the amounts are not disclosed beyond the 10 to 12 percent royalty range. The FDA decision on October 26, 2026 is the next catalyst, with the European, Chinese and Japanese reviews running in parallel. Strong Phase 3 results and priority review support the case, yet delays, label limits and slow uptake are real risks, and the FDA can act before or after its goal date. This is not a forecast.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...